Literature DB >> 24931430

Comorbidities and causes of death in the management of localized T1a kidney cancer.

Hiten D Patel1, Max Kates, Phillip M Pierorazio, Michael A Gorin, Gautam Jayram, Mark W Ball, Elias S Hyams, Mohamad Ezzeddine Allaf.   

Abstract

OBJECTIVE: The objectives of the present study were analyze specific comorbidities associated with survival and actual causes of death for patients with small renal masses, and to suggest a simplified measure associated with decreased overall survival specific to this population.
METHODS: The Surveillance, Epidemiology and End Results-Medicare database (1995-2007) was queried to identify patients with localized T1a kidney cancer undergoing partial nephrectomy, radical nephrectomy or deferring therapy. We explored independent associations of specific comorbidities with causes of death, and developed a simplified cardiovascular index. Cox proportional hazards, and Fine and Gray competing risks regression were used.
RESULTS: Of 7177 Medicare beneficiaries in the study population, 754 (10.5%) deferred therapy, 1849 (25.8%) underwent partial nephrectomy and 4574 (63.7%) underwent radical nephrectomy with none of the selected comorbidities identified in 3682 (51.3%) patients. Congestive heart failure, chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes and cerebrovascular disease were associated with decreased overall survival. The cardiovascular index provided good survival risk stratification, and reclassified 1427 (41%) patients with a score ≥1 on the Charlson Comorbidity Index to a 0 on the cardiovascular index with minimal concession of 5-year survival.
CONCLUSIONS: Congestive heart failure, chronic kidney disease, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes and cerebrovascular disease were associated with decreased overall survival among Medicare beneficiaries with small renal masses. The cardiovascular index could serve as a clinically useful prognostic aid when advising older patients that are borderline candidates for surgery or active surveillance.
© 2014 The Japanese Urological Association.

Entities:  

Keywords:  Epidemiology and End Results-Medicare; Surveillance; active surveillance; comorbidity; kidney cancer; renal cell carcinoma

Mesh:

Year:  2014        PMID: 24931430     DOI: 10.1111/iju.12527

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

Review 1.  Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry.

Authors:  Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

2.  Does diabetes mellitus play an independent prognostic role in kidney cancer?

Authors:  Johannes Breyer
Journal:  Ann Transl Med       Date:  2019-12

3.  Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes.

Authors:  Julie Y An; Mark W Ball; Michael A Gorin; Jiwon J Hong; Michael H Johnson; Christian P Pavlovich; Mohamad E Allaf; Phillip M Pierorazio
Journal:  Urology       Date:  2016-11-23       Impact factor: 2.649

4.  Simultaneous metastases of clear cell renal cell carcinoma to the urinary bladder and left retroperitoneal space: A case report and review of the literature.

Authors:  Hengping Li; Jianzhong Wang; Qiang Wei; Huan Wang
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

Review 5.  A Systematic Review of Research Gaps in the Evaluation and Management of Localized Renal Masses.

Authors:  Hiten D Patel; Emmanuel Iyoha; Phillip M Pierorazio; Stephen M Sozio; Michael H Johnson; Ritu Sharma; Eric B Bass; Mohamad E Allaf
Journal:  Urology       Date:  2016-08-16       Impact factor: 2.649

Review 6.  Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.

Authors:  Mohammad Haroon; Paul Sathiadoss; Rebecca M Hibbert; Satheesh Krishna Jeyaraj; Christopher Lim; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-07-10

7.  The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies.

Authors:  Luyao Chen; Hongzhao Li; Liangyou Gu; Xin Ma; Xintao Li; Yu Gao; Yu Zhang; Donglai Shen; Yang Fan; Baojun Wang; Xu Bao; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

8.  Nephron Sparing Surgery Has Better Oncologic Outcomes Than Extirpative Nephrectomy in T1a but Not in T1b or T2 Stage Renal Cell Carcinoma.

Authors:  You Luo; San-San Chen; Liang Bai; Li Luo; Xiang-Guang Zheng; Sen Wang
Journal:  Med Sci Monit       Date:  2017-07-18

9.  Outcomes of partial nephrectomy in patients who meet percutaneous ablation criteria.

Authors:  Kelly T Harris; Mark W Ball; Michael A Gorin; Mohamad E Allaf; Phillip M Pierorazio
Journal:  Cent European J Urol       Date:  2015-02-27

10.  Simultaneous or staged surgery in patients with kidney tumors and concomitant cardiac disease.

Authors:  Uladzimir Andrushchuk; Yury Ostrovsky; Sergey Krasny; Sergey Polyakov; Vladimir Zharkov; Alexander Rolevich; Svetlana Kurganovich; Valery Krutau; Siarhei G Amelchanka
Journal:  Cent European J Urol       Date:  2017-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.